Showing results (311-320 of 445) with videos related to
Sort By:
Pageof 45
JAMA Oncology|March 24, 2017
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical TrialHeikki Joensuu, Eva Wardelmann, Harri Sihto, et al.Physical Review Letters|September 26, 2012
Role of antisite disorder on preamorphization swelling in titanate pyrochloresY H Li, B P Uberuaga, C Jiang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized TrialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.European Journal of Cancer (Oxford, England : 1990)|December 1, 2019
Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcomaJoerg T Hartmann, Hans-G Kopp, Viktor Gruenwald, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 2013
Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998)R B Keus, R A Nout, J-Y Blay, et al.The Lancet. Oncology|April 17, 2012
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trialRalf-Dieter Hofheinz, Frederik Wenz, Stefan Post, et al.Cancer|April 17, 2014
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinibHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 5, 2003
The LPS receptor (CD14) links innate immunity with Alzheimer's diseaseK Fassbender, S Walter, S Kühl, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2007
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015C-H Köhne, J De Greve, J T Hartmann, et al.The Lancet. Oncology|March 13, 2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialIan Judson, Jaap Verweij, Hans Gelderblom, et al.Pageof 45